Gilead Sciences Q3 product sales rise 13% to $8.3B, lifts full-year base business revenue guidance

Gilead Sciences reported Q3 product sales of $8.3 billion, up 13% year-over-year. Excluding Veklury, sales rose 16% to $8.2 billion. HIV product sales grew 18% to $6.2 billion. GAAP EPS was $1.94, non-GAAP EPS $2.55. The company raised full-year base business revenue guidance by $1.6 billion since the start of 2026.